Gerald Goodman - Nutriband CFO Officer
| NTRB Stock | USD 6.16 0.71 13.03% |
Insider
Gerald Goodman is CFO Officer of Nutriband
| Age | 76 |
| Address | 121 South Orange Avenue, Orlando, FL, United States, 32801 |
| Phone | 407 377 6695 |
| Web | https://nutriband.com |
Nutriband Management Efficiency
The company has return on total asset (ROA) of (0.3588) % which means that it has lost $0.3588 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7308) %, meaning that it created substantial loss on money invested by shareholders. Nutriband's management efficiency ratios could be used to measure how well Nutriband manages its routine affairs as well as how well it operates its assets and liabilities. As of June 4, 2024, Return On Tangible Assets is expected to decline to -3.15. In addition to that, Return On Capital Employed is expected to decline to -0.78. At present, Nutriband's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 11.6 K, whereas Total Assets are forecasted to decline to about 5.5 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Victoria Rac | Bio Path Holdings | N/A | |
| Alexander Klibanov | Pulmatrix | 74 | |
| Janice Hitchcock | Acumen Pharmaceuticals | N/A | |
| Julie MBA | Day One Biopharmaceuticals | 42 | |
| MBA CMA | Pulmatrix | 69 | |
| Julie Bockenstette | Acumen Pharmaceuticals | N/A | |
| Waldemar Priebe | Moleculin Biotech | N/A | |
| Mike Preigh | Day One Biopharmaceuticals | N/A | |
| Anthony MBA | Capricor Therapeutics | 38 | |
| PharmD Chiodin | Day One Biopharmaceuticals | N/A | |
| FACP MD | Moleculin Biotech | 70 | |
| Louis Ploth | Moleculin Biotech | 70 | |
| Jason Cavalier | Lyra Therapeutics | 51 | |
| Arnon Rosenthal | Annexon | 68 | |
| Melissa BradfordKlug | Akari Therapeutics PLC | 54 | |
| Ming Yin | Bolt Biotherapeutics | N/A | |
| MBA MD | Moleculin Biotech | N/A | |
| Alan MacKenzie | Bio Path Holdings | N/A | |
| Karen Bergman | Bolt Biotherapeutics | N/A | |
| Ted Yednock | Annexon | 66 | |
| Miles Nunn | Akari Therapeutics PLC | 55 | |
Management Performance
| Return On Equity | -0.73 | ||||
| Return On Asset | -0.36 |
Nutriband Leadership Team
Elected by the shareholders, the Nutriband's board of directors comprises two types of representatives: Nutriband inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nutriband. The board's role is to monitor Nutriband's management team and ensure that shareholders' interests are well served. Nutriband's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nutriband's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Patrick Ryan, Chief Technical Officer | ||
| Tyler Overk, President Intelligence | ||
| Gerald Goodman, CFO Officer | ||
| Alan Smith, Head of 4P Therapeutics and Clinical Development | ||
| Serguei Melnik, President, Founder | ||
| Gareth Sheridan, CEO, Director | ||
| Jeffrey PharmD, Chief Officer |
Nutriband Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nutriband a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.73 | ||||
| Return On Asset | -0.36 | ||||
| Profit Margin | (2.63) % | ||||
| Operating Margin | (2.49) % | ||||
| Current Valuation | 67.26 M | ||||
| Shares Outstanding | 11.04 M | ||||
| Shares Owned By Insiders | 44.00 % | ||||
| Shares Owned By Institutions | 2.31 % | ||||
| Number Of Shares Shorted | 17.3 K | ||||
| Price To Earning | (15.98) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| MSFT | Microsoft | |
| CRM | Salesforce | |
| GOOG | Alphabet Inc Class C |
Additional Information and Resources on Investing in Nutriband Stock
When determining whether Nutriband offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Nutriband's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Nutriband Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Nutriband Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nutriband. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Nutriband Stock refer to our How to Trade Nutriband Stock guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nutriband. If investors know Nutriband will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nutriband listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.77) | Revenue Per Share 0.262 | Quarterly Revenue Growth (0.01) | Return On Assets (0.36) | Return On Equity (0.73) |
The market value of Nutriband is measured differently than its book value, which is the value of Nutriband that is recorded on the company's balance sheet. Investors also form their own opinion of Nutriband's value that differs from its market value or its book value, called intrinsic value, which is Nutriband's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nutriband's market value can be influenced by many factors that don't directly affect Nutriband's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nutriband's value and its price as these two are different measures arrived at by different means. Investors typically determine if Nutriband is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nutriband's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.